PASADENA, Calif., December 02, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough ...
Arrowhead Game Studios has already begun work on its next game, but how does a developer follow a galactic success as beloved as Helldivers 2? Former CEO and current CCO Johan Pilestedt says whatever ...
JEFFERSON CITY, Mo. -- As the Kansas City Chiefs weigh whether to play future games in a renovated Arrowhead Stadium or a proposed dome in Kansas, Missouri Gov. Mike Kehoe on Tuesday floated a ...
The Chiefs eventually will choose between the renovation of Arrowhead Stadium in Missouri and the construction of a domed stadium across the border in Kansas. There’s a possibility that a roof could ...
The Chiefs continue to move toward an inevitable decision between renovating Arrowhead Stadium and building a new stadium. On Monday, Chiefs owner Clark Hunt addressed the status of the team’s effort ...
Apple appears to be winding down support of Clips, with the company removing Clips from the App Store and saying it will no longer be making any updates. In a support page on the Apple website, the ...
Among the quiet pines above Lake Arrowhead, a battle is underway, one that will decide who calls the shots in the unincorporated community nestled in the San Bernardino Mountains. In 1915, property ...
Pasadena-based Arrowhead Pharmaceuticals Inc. has announced another major licensing deal with a pharma giant. This one is with Basel, Switzerland-based Novartis for $200 million in upfront payment and ...
Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that Arrowhead's potential rival to Tryngolza breaches a patent. Arrowhead claims ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for ...
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for ...
Novartis has been on a deal-making spree in 2025, including buyouts and licensing pacts, as it prepares for looming patent expirations on several blockbuster medicines. H.C. Wainwright analysts said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback